Search results
Privacy Policy and Terms of Use
…refers to third-party companies or individuals employed by the Company to facilitate the Service, to provide the Service on behalf of the Company, to perform services related to the Service…
Leadership
At Ridgeback, we come to work every day to serve patients who need champions. Please read and learn about our leadership team – focused individuals dedicated to fighting disease and…
EBANGA™
…it remains available to patients free of charge in Ebola-stricken countries. Clinical Trials More Information For more information EBANGA™ including the U.S. Prescribing Information, please go to: www.EBANGA.com. Recent Press…
George Painter, PhD
…which have led to approved, commercially available drugs or combinations of drugs for the treatment of HIV, Hepatitis B, smallpox, and coronavirus infections. He has published more than 120 peer-reviewed…
About Us
Founded in 2016, Ridgeback Biotherapeutics is a biotech company focused on developing transformational therapies to resolve or mitigate the effects of emerging infectious diseases. Ridgeback is committed, proud, and humbled…
Career Opportunities
Ridgeback Biotherapeutics commits resources and expertise for undefined and poorly understood diseases early in the pharmaceutical development cycle, at a time generally when few stakeholders are prepared to make the…
Pipeline
…20,000 companies, we are one of the 150 companies who have an FDA approved biologic that serves patients. Our patient-guided mission allows us to work on programs that we believe…
Home
Our Difference: We commit resources and expertise for poorly-understood diseases. Tens of millions of people worldwide suffer every year from known and emerging infectious diseases that have few therapeutic options,…
Expanded Access Policy
…indication, suggesting that a clinically meaningful benefit may be expected and that the benefits outweigh any potential risks. Providing investigational medicine through expanded access will not compromise clinical trials or…
Lagevrio (molnupiravir)
Lagevrio (molnupiravir) is a direct-acting oral, broad-spectrum antiviral agent in clinical development as a treatment for COVID-19. Ridgeback has completed Phase 1 and Phase 2 studies. The program has advanced…